Marinus Pharmaceuticals, Inc. Sustainability Profile
Marinus Pharmaceuticals, Inc., a leading biopharmaceutical company headquartered in the United States, focuses on developing innovative therapies for patients with rare neurological disorders. Founded in 2003, Marinus has made significant strides in the industry, particularly with its flagship product, Ztalmy (ganaxolone), which addresses seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder. With a commitment to advancing treatment options, Marinus Pharmaceuticals operates primarily in the neurology sector, leveraging its expertise in neuroactive steroids to create unique therapeutic solutions. The company has established a strong market position, recognised for its dedication to improving patient outcomes and its ongoing research initiatives. Through its pioneering approach, Marinus continues to make notable contributions to the field of neurology, aiming to transform the lives of those affected by challenging conditions.
DitchCarbon Score
How does Marinus Pharmaceuticals, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Marinus Pharmaceuticals, Inc.'s score of 42 is higher than 61% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Marinus Pharmaceuticals, Inc., headquartered in the US, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. The company has not established any documented reduction targets or climate pledges, which suggests a lack of formal commitments to reducing its carbon footprint at this time. However, it is important to note that Marinus Pharmaceuticals, Inc. is a current subsidiary of Immedica Pharma AB. Any potential climate initiatives or emissions data may be influenced by the parent company's strategies and commitments. As of now, there are no specific emissions figures or reduction initiatives reported from Immedica Pharma AB that could be cascaded to Marinus Pharmaceuticals. In the broader context of the pharmaceutical industry, companies are increasingly recognising the importance of sustainability and climate action. While Marinus Pharmaceuticals has yet to disclose its own commitments, the industry trend towards transparency and accountability in carbon emissions may prompt future disclosures and initiatives.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | |
|---|---|---|
| Scope 1 | 36,700 | 00,000 |
| Scope 2 | 300 | - |
| Scope 3 | 156,101,000 | 00,000,000 |
How Carbon Intensive is Marinus Pharmaceuticals, Inc.'s Industry?
How Carbon Intensive is Marinus Pharmaceuticals, Inc.'s Location?
Marinus Pharmaceuticals, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Marinus Pharmaceuticals, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
